Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495180 | 0.90 | POLB (0.58) | LTA4HPOLBHRH3MEN1KMT2A | |
| SCHEMBL17415 | 0.90 | POLB (0.58) | LTA4HPOLBHRH3MEN1KMT2A | |
| SCHEMBL16738 | 0.90 | POLB (0.58) | LTA4HPOLBHRH3MEN1KMT2A | |
| SCHEMBL29119634 | 0.88 | POLB (0.56) | LTA4HPOLBHRH3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL12078757 | 0.88 | POLB (0.56) | LTA4HPOLBHRH3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL12078541 | 0.88 | POLB (0.56) | LTA4HPOLBHRH3MEN1KMT2A | |
| SCHEMBL8904123 | 0.88 | POLB (0.56) | LTA4HPOLBHRH3MEN1KMT2A | |
| SCHEMBL8201261 | 0.88 | POLB (0.56) | LTA4HPOLBHRH3MEN1KMT2A | |
| SCHEMBL30589117 | 0.88 | POLB (0.56) | LTA4HPOLBHRH3MEN1KMT2A | |
| SCHEMBL5504868 | 0.79 | HRH3 (0.49) | LTA4HPOLBHRH3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| US-8198280-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-06-12 | — | — | US | disclosed |
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | disclosed |
| EP-1844032-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-07-13 | — | — | EP | disclosed |
| US-20110086864-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-7868009-B2 | N-hydroxyamide derivatives and use thereof | Merck Serono, S.A. (CH) | 2011-01-11 | — | — | US | disclosed |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | LABORATOIRES SERONO S.A. (CH) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086864-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | LTA4H 63/4885POLB 2290/4885HRH3 18/4885 |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | HNMT, ALOX5, HCAR2 | LTA4H 50/4885POLB 2530/4885HRH3 29/4885 |
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | LTA4H 63/4885POLB 2290/4885HRH3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.